Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

23.95USD
19 Oct 2018
Change (% chg)

$1.25 (+5.51%)
Prev Close
$22.70
Open
$23.39
Day's High
$24.05
Day's Low
$22.90
Volume
875,418
Avg. Vol
658,162
52-wk High
$27.32
52-wk Low
$8.68

Latest Key Developments (Source: Significant Developments)

Immunomedics Enters Exchange Agreements With Outstanding 4.75 pct Convertible Note Holders
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS-ON OCT 2, ENTERED INTO EXCHANGE AGREEMENTS WITH LIMITED NUMBER OF HOLDERS OF OUTSTANDING 4.75% CONVERTIBLE SENIOR NOTES DUE 2020.IMMUNOMEDICS INC - COMPANY ANTICIPATES THE EXCHANGES WILL BE COMPLETED ON OR ABOUT OCTOBER 5, 2018 - SEC FILING.IMMUNOMEDICS - UPON COMPLETION OF EXCHANGES, AGGREGATE AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS INC - UPON COMPLETION OF EXCHANGES, AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE NOTES IS EXPECTED TO BE REDUCED TO ABOUT $7.1 MILLION.IMMUNOMEDICS-AGREED TO EXCHANGE ABOUT $12.9 MILLION CONVERTIBLE NOTES HELD BY NOTEHOLDERS FOR ABOUT 2.57 MILLION NEWLY ISSUED SHARES OF CO'S COMMON STOCK.  Full Article

Immunomedics And Samsung Biologics Announce Strategic Manufacturing Partnership
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Samsung Biologics Co Ltd <207940.KS>::IMMUNOMEDICS AND SAMSUNG BIOLOGICS ANNOUNCE STRATEGIC MANUFACTURING PARTNERSHIP.IMMUNOMEDICS INC - TECHNOLOGY TRANSFER AND ENGINEERING RUNS FOR NEW ANTIBODY PRODUCTION ARE CURRENTLY UNDERWAY.IMMUNOMEDICS INC - COMMERCIAL PRODUCTION EXPECTED TO BEGIN IN 2020 UNDER PARTNERSHIP.IMMUNOMEDICS - SAMSUNG WILL MANUFACTURE CO'S ' PROPRIETARY HUMANIZED ANTIBODY, HRS7, AT ITS MANUFACTURING FACILITIES IN INCHEON, SOUTH KOREA.  Full Article

Immunomedics Says CFO Michael Garone Resigned
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Immunomedics Inc ::SAYS CFO MICHAEL GARONE RESIGNED.SAYS USAMA MALIK APPOINTED INTERIM CFO.APPOINTED WILLIAM FRICKER, TO SERVE AS COMPANY'S PRINCIPAL ACCOUNTING OFFICER.SAYS GARONE SHALL REMAIN THE COMPANY’S VICE PRESIDENT, FINANCE, UNTIL MAY 18, 2019 - SEC FILING.  Full Article

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA
Monday, 21 May 2018 

May 21 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION.IMMUNOMEDICS INC - FILING IS BASED ON PHASE 1/2 DATA OF SACITUZUMAB GOVITECAN IN MTNBC.  Full Article

Immunomedics Reports Q3 Loss Per Share $0.21
Wednesday, 9 May 2018 

May 9 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.21.Q3 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $500,000 VERSUS $1.3 MILLION.Q3 REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Immunomedics Inc ::IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION.IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE.IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

Immunomedics announces first quarter fiscal results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunomedics Inc :Immunomedics announces first quarter fiscal 2018 results and provides corporate update.Q1 loss per share $0.97.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Immunomedics Inc - qtrly ‍total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016​.  Full Article

Immunomedics reports Q4 loss per share $0.48
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Immunomedics Inc :Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline.Q4 revenue fell 33 percent to $600,000.Q4 revenue view $2.3 million -- Thomson Reuters I/B/E/S.Q4 loss per share $0.48.Q4 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Immunomedics Inc - ‍cash, cash equivalents, and marketable securities totaled $154.9 million as of june 30, 2017​.Immunomedics Inc - ‍company expects to present final results of IMMU-132 in mtnbc that will form basis of bla submission later this year​.Immunomedics Inc - ‍believe that current financial resources are sufficient to support operations through september 2018​.  Full Article

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Immunomedics announces Q2 fiscal 2017 results and clinical program developments
Thursday, 9 Feb 2017 

Immunomedics Inc : Immunomedics announces second quarter fiscal 2017 results and clinical program developments . Immunomedics Inc says total costs and expenses for quarter ended December 31, 2016 were $15.7 million, compared to $16.4 million for same quarter in fiscal 2016 . Q2 loss per share $0.23 .Q2 revenue fell 43 percent to $400,000.  Full Article

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION